| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 3 | +26,765 | 9.6% | $9.04 | +$241,896 |
| Sells | 4 | -253,234 | 90% | $15.77 | -$3,992,845 |
| Net | -1 | -226,469 | -81% | -$3,750,948 |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Michael A. Metzger | Chief Executive Officer, Director | $4,902,191 | -$2,975,556 | -38% | 08 Sep 2025 |
| Steve M. Sabus | Chief Commercial Officer | $4,257,000 | 05 Dec 2022 | ||
| Dennis Podlesak | Director | $3,037,947 | -$875,100 | -22% | 14 Aug 2025 |
| Neil Gallagher | President, Head of R&D | $2,938,138 | -$71,597 | -2.4% | 10 Feb 2025 |
| Keith A. Goldan | Chief Financial Officer | $2,869,700 | -$70,592 | -2.4% | 01 Dec 2025 |
| Catherine Madigan | Chief Medical Officer | $2,128,500 | 02 Feb 2023 | ||
| Jennifer Jarrett | Director | $1,802,682 | 05 Feb 2025 | ||
| Pierre Legault | Director | $1,802,682 | 05 Feb 2025 | ||
| William Meury | Director | $1,802,682 | 05 Feb 2025 | ||
| Aleksandra Rizo | Director | $1,280,545 | 05 Feb 2025 | ||
| Keith Katkin | Director | $911,200 | +$91,120 | +11% | 19 May 2025 |
| Michael L. Meyers | SVP, Chief Medical Officer | $760,935 | 02 Feb 2022 | ||
| Martin H. Huber Jr. | Director | $710,210 | +$44,950 | +6.8% | 19 May 2025 |
| Briggs Morrison | Director | $636,283 | 07 Feb 2024 | ||
| Fabrice Egros | Director | $584,483 | 02 Feb 2022 | ||
| Alexander Nolte | Chief Accounting Officer | $328,950 | 02 Feb 2023 | ||
| Nicholas A.J. Botwood | Head of R&D, CMO | $316,309 | +$105,826 | +50% | 16 May 2025 |
| Peter Ordentlich | Chief Scientific Officer | 15 Feb 2023 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|